Non-small cell lung cancer (NSCLC) often harbors oncogenic driver alterations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Kirsten rat sarcoma viral oncogene homolog (KRAS), which can be effectively targeted with tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.